Buy Metropolis Healthcare Ltd for the Target Rs 675 by Emkay Global Financial Services Ltd
We attended the investor and analyst meet of Metropolis Healthcare (MHL) and came back enthused by the profitable growth prospects presented by the company. KTAs:
1) Management reiterated its FY27 guidance of 14-15% revenue growth (assuming no price increase) and EBITDA margin expansion of 100-150bps on the back of accelerating network expansion and improving center-to-lab ratio, resulting in better utilization.
2) Management believes the growth will be primarily volume-led, with increasing share of TruHealth (up to 25% of revenue) and Specialty testing portfolio (up to 45% of revenue) as MHL invests in cutting edge technology and clinician engagement.
3) Focus on the digital channel (25% of revenue) has started yielding meaningful results, with customers secured via the digital medium providing almost 2x LTV vs offline channels.
4) MHL maintains discipline while executing M&As and will continue with a similar playbook as in the past (strong regional brand, lab/scientific credibility and scalability).
5) Shift toward quality organized players, along with growing awareness about preventive testing, is likely to benefit market leaders like MHL. Sep-27E TP of Rs675 is unchanged (DCF-based), implying FY28E PER of 45x (~5% discount to DLPL) and FY28E EV/OCF of 29x; maintain BUY.
MHL's growth playbook - Penetration, Premiumization, M&A
MHL's long-term strategy centers on delivering profitable growth through uncompromising quality—anchored in scientific excellence and increasingly enabled by AI-led automation on its lab and customer-acquisition journey. MHL plans to deepen network penetration by expanding owned centers to ~1,000 (from ~750 now) while improving throughput per center and broadening the adjacencies bundled into its offerings. On the B2C front, this is anchored on TruHealth, targeted to scale from 18% to >25% of revenue over the next three years through 100 new/upgraded mini-hubs and the addition of radiology and consultation to existing wellness packages. In parallel, MHL is raising its specialty mix from 40% to ~45% of revenue, leveraging its genomics and oncology testing capabilities built through the Core acquisition, while B2B growth is being calibrated toward margin-accretive accounts. Inorganic growth remains a core lever of this strategy, with M&A used selectively to enter new geographies and add new capabilities – underwritten by valuation guardrails and funded from internal accruals.
Margin trajectory to fortify over the next 2-3Y
Management targets margin expansion to 27-28% over the medium term, aided by levers such as
1) premiumization through a specialty and genomics mix,
2) improved lab throughput (center-to-lab ratio moving from 24:1 to ~35:1),
3) platform standardization
4) AI-led lab automation
5) convergence of the Core acquisition's margin toward >20% by Year-3 of acquisition. MHL remains confident about optimal utilization of its lab network (accelerated expansion during FY21-25) to continue aiding margins, along with volume-led operating leverage. Robust cash generation (OCF/EBITDA in FY26: 87%), a net-cash balance sheet (Rs1.8bn, as of Mar-26), and improving return ratios (FY28E ROCE at ~20%) provide comfort on valuations
For More Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354
